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Background: Long-lasting insecticidal nets (LLINs) are a key malaria control intervention, but their effectiveness is
threatened by resistance to pyrethroid insecticides. Some new LLINs combine pyrethroids with piperonyl butoxide
(PBO), a synergist that can overcome P450-based metabolic resistance to pyrethroids in mosquitoes. In 2017–2018,
the Ugandan Ministry of Health distributed LLINs with and without PBO through a national mass-distribution
campaign, providing a unique opportunity to rigorously evaluate PBO LLINs across different epidemiological settings.
Methods/design: Together with the Ministry of Health, we embedded a cluster-randomised trial to evaluate the
impact of LLINs delivered in the 2017–2018 national campaign. A total of 104 clusters (health sub-districts) in Eastern
and Western Uganda were involved, covering 48 of 121 (40%) districts. Using adaptive randomisation driven by the
number of LLINs available, clusters were assigned to receive one of four types of LLINs, including two brands with PBO:
1) PermaNet 3.0 (n = 32) and 2) Olyset Plus (n = 20); and two without PBO: 3) PermaNet 2.0 (n = 37) and 4) Olyset Net
(n = 15). We are conducting cross-sectional community surveys in 50 randomly selected households per cluster (5200
households per survey) and entomological surveillance for insecticide resistance in up to 10 randomly selected
households enrolled in the community surveys per cluster (1040 households per survey) at baseline and 6, 12, and 18
months after LLIN distribution. Net durability and bio-efficacy will be assessed in 400 nets withdrawn from households
with replacement at 12months. The primary trial outcome is parasite prevalence as measured by microscopy in
children aged 2–10 years in the follow-up surveys.
Discussion: PBO LLINs are a promising new tool to reduce the impact of pyrethroid resistance on malaria control. The
World Health Organization has issued a preliminary endorsement of PBO LLINs, but additional epidemiological evidence
of the effect of PBO LLINs is urgently needed. The results of this innovative, large-scale trial embedded within a routine
national distribution campaign will make an important contribution to the malaria control policy in Uganda and
throughout Africa, where pyrethroid resistance in malaria vectors has increased dramatically. This model of evaluation
could be a paradigm for future assessment of malaria control interventions.
Trial registration: ISRCTN, ISRCTN17516395. Registered on 14 February 2017.
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Insecticide resistanceBackground
Since 2000, coverage of malaria control interventions
has expanded considerably across Africa, resulting in im-
pressive reductions in malaria burden [1]. However,
there is recent evidence that reductions in malaria bur-
den have stalled in some countries [2]. In Uganda, pro-
gress on reducing malaria transmission has been slow,
despite the scale-up of long-lasting insecticidal nets
(LLINs), indoor residual spraying (IRS), and treatment of
symptomatic malaria cases with artemisinin-based com-
bination therapies, and control gains have been difficult
to sustain [3–6]. Recent evidence that malaria incidence
is rising in Uganda underscores the need to intensify
malaria control efforts [2, 7].
LLINs reduce morbidity and mortality caused by mal-
aria across a range of epidemiological settings and are
the most widely used vector control tool in Africa [8, 9].
To achieve and maintain universal coverage with LLINs,
the World Health Organization (WHO) recommends
the distribution of one LLIN for every two individuals at
risk of malaria through mass campaigns conducted every
3 years [10]. In Uganda, major efforts have been made to
achieve universal coverage of LLINs [11], but LLIN
coverage remains below target [2] and the impact of
LLINs has been lower than expected in some areas of
Uganda [5, 6]. Currently, all LLINs are treated with pyr-
ethroid insecticides due to their favourable safety profile
at low doses, repellent effects, rapid killing, and low cost.
However, pyrethroid resistance has become widespread
in Africa and presents a major threat to malaria control
[12, 13]. Recently completed trials suggest that, even in
areas of increased insecticide resistance, users of LLINs
have lower prevalence and incidence of malaria than
non-users, although these studies have not quantified
the extent to which the community or mass effect may
have been lost [14, 15].
Pyrethroid resistance is commonly mediated through
two main mechanisms, including ‘knock-down resistance’
caused by target-site mutations in the receptor for pyre-
throids (kdr) and metabolic resistance [13]. One of the
most important metabolic resistance mechanisms is allelic
and expression changes in cytochrome p450 enzymes that
detoxify pyrethroids [16, 17]. To combat P450-mediated
resistance, a new generation of LLINs has been developed
which combines a pyrethroid insecticide with a synergist,
piperonyl butoxide (PBO), which inhibits cytochrome
P450s, and may thereby restore pyrethroid susceptibility[18]. Two brands of PBO nets have WHOPES (WHO
Pesticide Evaluation Scheme) recommendations [19, 20]:
PermaNet® 3.0 (Vestergaard Frandsen SA, Denmark) and
Olyset® Plus (Sumitomo Chemical). Although both nets in-
corporate PBO, the characteristics of the PBO nets, and of
the conventional non-PBO nets produced by both com-
panies (PermaNet® 2.0 and Olyset® Net), vary in terms of
insecticide used, concentrations, net weight, and construc-
tion [19, 20].
One epidemiological study of the effectiveness of
LLINs with PBO has been conducted in Tanzania [21].
In this small, cluster-randomised, controlled trial which
compared the impact of Olyset® Plus nets (with PBO) to
Olyset® Nets (without PBO), parasite prevalence was sig-
nificantly lower in the PBO LLIN arm at 9, 16, and 21
months after the intervention. Based on these results,
the WHO has provided an interim endorsement of PBO
LLINs, recommending that PBO LLINs be deployed in
areas of intermediate-level pyrethroid resistance due at
least in part to metabolic mechanisms [22]. However,
the impact of LLINs with PBO is expected to vary
according to transmission intensity, bioavailability and
retention of PBO, and the mechanisms and level of pyr-
ethroid resistance of local vectors. Additional evidence
of the impact of combination LLINs (with PBO) is ur-
gently needed.
In 2017–2018, the Ugandan Ministry of Health distrib-
uted LLINs with and without PBO through a national
mass-distribution campaign, providing a unique oppor-
tunity to rigorously evaluate PBO LLINs across a variety
of malaria transmission intensities, vector ecologies, and
insecticide resistance patterns. In close collaboration
with the Ministry of Health, we are conducting a
cluster-randomised trial to evaluate the community-level
impact of the LLINs delivered in the 2017–2018 national
campaign at an unprecedented scale in Eastern and
Western Uganda. This innovative, evaluation approach
could be adopted for future assessments of malaria con-
trol interventions.
Primary objective and hypothesis
We address the following research question: ‘Are com-
bination LLINs (with PBO) more effective than conven-
tional LLINs (without PBO) for malaria control in
Uganda, an area with high-level P450-based pyrethroid
resistance?’ We will test the hypothesis that parasite
prevalence will be lower in intervention clusters (health
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control clusters (health sub-districts randomised to con-
ventional nets) and undertake a sub-group analysis
stratified by region (Eastern and Western regions).
Secondary objectives and hypotheses
In addition, the following secondary objectives will be
addressed:
1 To evaluate the impact of PermaNet 3.0 (with PBO)
compared with PermaNet 2.0 (without PBO) on
parasite prevalence. We will test the hypothesis that
parasite prevalence will be lower in intervention
clusters (PermaNet 3.0 nets) than in control
clusters (PermaNet 2.0 nets).
2 To evaluate the impact of Olyset Plus (with PBO)
compared with Olyset Net (without PBO) on
parasite prevalence. We will test the hypothesis that
parasite prevalence will be lower in intervention
clusters (Olyset Plus nets) than in control health
clusters (Olyset Nets).
3 To determine the factors associated with the
effectiveness of combination LLINs (with PBO)
compared with conventional LLINs (without PBO),
with a focus on the level of pyrethroid resistance.
We will test the hypothesis that LLINs with PBO
will be more effective than LLINs without PBO inFig. 1 Trial timeline. LLIN long-lasting insecticidal netsettings with higher frequencies of P450-mediated
pyrethroid resistance.
4 To assess net durability, bio-efficacy, survivorship,
and use. We will conduct cross-sectional surveys to
determine net survivorship and use, and to measure
attrition, and will supplement these with laboratory
assessments of net durability and bio-efficacy.Study design
The study includes 104 health sub-districts from 48 dis-
tricts in Eastern and Western Uganda. The unit of
randomisation is one health sub-district (cluster). Clus-
ters were randomly assigned to receive one of four types
of LLINs, including two LLINs with PBO: 1) PermaNet
3.0 (n = 32) and 2) Olyset Plus (n = 20); and two LLINs
without PBO: 3) PermaNet 2.0 (n = 37) and 4) Olyset
Net (n = 15). Prior to distribution of the nets, baseline
surveys of community households and children aged 2–
10 years, and entomological surveillance for insecticide
resistance monitoring, were conducted (Fig. 1). LLINs
were distributed within the study area by the Ministry of
Health between March 2017 and March 2018. The
evaluation includes follow-up community and entomol-
ogy surveys at 6, 12, and 18 months post-distribution,
plus assessment of net durability and bio-efficacy at 12
months. The primary outcome of the trial is parasite
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10 years in the follow-up community surveys.Methods
Study setting
A total of 104 clusters in Eastern and Western Uganda
were included in the study (Fig. 2). Areas scheduled to
receive IRS with pirimiphos-methyl (Actellic) were ex-
cluded due to an interim WHO recommendation (since
relaxed) that PBO nets should not be used in areas of
Actellic spraying due to the possibility of antagonistic
effects [22]. The study area represents five of the 10 geo-
graphic regions included in the Uganda Malaria Indica-
tor Survey [23].Fig. 2 Map of the study area showing allocation of nets by cluster (healthSensitisation
Prior to the study, project partners in the Ministry of
Health and other key partners at the national and local
level engaged with stakeholders at the district and com-
munity level in participating districts, including the Dis-
trict Health Officers and Malaria Focal Persons, local
leaders, village health team (VHT) members, and other
key opinion leaders. Study personnel used an informa-
tion sheet to guide sensitisation discussions.
Baseline community surveys
Cross-sectional surveys of community residents living in
households randomly selected from each cluster were
conducted from March to June 2017, prior to distribu-
tion of the LLINs. The community survey consisted ofsub-district)
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administered to heads of households; and 2) a clinical
survey of children aged 2–10 years.
Sampling frame
A two-stage cluster sampling procedure was applied
using enumeration areas identified in the 2014 national
census as the primary sampling unit [23, 24]. Ten enu-
meration areas within each of the 104 health
sub-districts were randomly selected by the Uganda Bur-
eau of Statistics (UBOS) using probability proportionate
to size sampling. Households within each selected enu-
meration area were mapped and enumerated by the
study team. A random sample of mapped households
was selected from each enumeration area to generate a
list of households to approach for recruitment.
Recruitment and enrolment
Households from the recruitment list were approached
until five households from each enumeration area were
enrolled (50 households per health sub-district, 5200
total). When a household was identified, study personnel
briefly described the purpose of the study to the head of
the household (or their designate) in the appropriate lan-
guage. Households were included if: 1) at least one resi-
dent of the household was between 2 and 10 years of age;
2) at least one adult aged 18 years or older was present; 3)
the adult was a usual resident who slept in the sampled
household on the night before the survey; and 4) the adult
resident agreed to provide informed consent for the
household survey. Households were excluded if: 1) the
dwelling was destroyed or not found; 2) the household
was vacant; or 3) there was no adult resident at home on
more than three occasions. Written consent to participate
in the study was sought from an adult resident for all
households fulfilling the selection criteria.
Household survey
Upon enrolment, a household survey questionnaire,
adapted from prior cross-sectional community surveys
conducted in Uganda including the national Malaria In-
dicator Survey [23, 25–27], was administered to heads of
households or their designate using a hand-held tablet
computer. Information was gathered on the characteris-
tics of households and residents, proxy indicators of
wealth including ownership of assets, and ownership
and use of LLINs in the households.
Clinical survey
All children aged 2–10 years present in enrolled house-
holds were eligible to participate in the clinical survey.
Sample collection for laboratory testing was performed
in children identified from the household questionnaire
if they met the following selection criteria: 1) were 2–10years of age; 2) were usually resident and present in the
sampled household on the night before the survey; 3)
had provision of informed consent by a parent/guardian;
and 4) had assent of child aged 8 years or older. If a
child was not present of the day of the survey they were
excluded. Finger-prick blood samples were taken from
all eligible children for thick smear and for all eligible
children 2–4 years of age for haemoglobin measurement.
A filter paper blood sample was also obtained for future
molecular testing.
Management of ill participants
Clinical survey participants who had a temperature ≥
38.0 °C or who reported fever in the past 48 h had a rapid
diagnostic test (RDT) performed (SD Bioline Malaria Ag
P.f or P.f/Pan, Standard Diagnostics, Inc.). Participants
with a positive RDTand no evidence of danger signs or se-
vere malaria were treated with artemether-lumefantrine,
which is the first-line treatment for uncomplicated malaria
in Uganda. Participants with a positive RDT and evidence
of danger signs of severe disease were referred for further
evaluation and treatment. Any participant with other con-
cerning clinical symptoms were also referred to an appro-
priate healthcare facility, following guidelines outlined in
standard operating procedures.
Baseline entomology surveys for insecticide resistance
monitoring
Entomology surveys were carried out concurrently with
the baseline community surveys to collect mosquito
specimens for insecticide resistance monitoring. In each
cluster, up to ten households were selected randomly
from the list of 50 households enrolled into the commu-
nity surveys. Study personnel re-visited households on
the list of randomly selected households to carry out re-
cruitment, and briefly described the purpose of the mos-
quito collections in the appropriate language to the head
of household (or their designate) before proceeding with
sampling. Mosquitoes were sampled from enrolled
households in the mornings (from dawn until 10 am)
using Prokopack aspirators to collect mosquitoes resting
indoors on walls [28]. A brief questionnaire was also ad-
ministered to gather information on household charac-
teristics and the use of malaria prevention measures.
Female anopheles mosquitoes were identified, and were
stored at 4 °C in the regional field sites prior to shipment
to Kampala and onto the Liverpool School of Tropical
Medicine (LSTM) for molecular analysis.
Assignment of interventions
Initial randomisation and net allocation
The randomisation was carried out by a member of the
study team based outside of Uganda who was not dir-
ectly involved in the field work. The total number of
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to the four study arms) and the estimated number of
LLINs needed for each health sub-district were estab-
lished prior to the randomisation (Table 1). Given the
restriction on the number of nets to be distributed in
each study arm, adaptive randomisation was applied
using the following steps: 1) A random number between
0 and 1 was generated for each cluster using STATA
(StataCorp, Texas, USA). 2) Cumulative probability
ranges were generated for each of the four types of net
based on the targeted number of each individual type of
net/targeted number of total nets. 3) The first cluster
was assigned to their intervention based on which cu-
mulative probability range the corresponding random
number fell into. 4) Step 2 above was repeated after re-
moving the number of targeted nets assigned to the
cluster for the corresponding type of net and the total
number of nets. 5) The next cluster was assigned to their
intervention based on which revised cumulative prob-
ability range the corresponding random number fell into.
6) This process was repeated until all clusters were allo-
cated to an intervention. The process was stratified by
region, with 66 clusters in the Western region and 38
clusters in the Eastern region since although insecticide
resistance is very well characterised in Eastern Uganda,
little is known about patterns in the West [17, 29–31].
Areas scheduled to receive IRS with pirimiphos-methyl
(Actellic) were excluded [22]. Given the nature of the
trial, allocation of the LLINs was not blinded.
LLIN distribution
The LLINs were distributed by the Ministry of Health and
supporting partners according to national guidelines [32].
Household-level registration data were collected door-to-
door in each village to determine the number of nets
needed [32]. The LLINs were imported into Uganda and
stored in warehouses in Kampala. The Ministry of Health
was responsible for issuing the LLINs according to the net
allocation list. Nets were taken out of the Kampala ware-
houses and placed onto trucks for transport to sub-county
stores. Using the household registration data, and inTable 1 Revised study interventions, target number of nets, and fina
Type of LLIN Targeted total number of nets
for distribution
Cumulative
nets allocate
Original
randomisation
Final
randomisation
Original
randomisatio
PermaNet 2.0 3,217,360 3,743,320 3,220,280
PermaNet 3.0 (contains PBO) 4,100,000 3,570,640 4,101,840
Olyset Net 650,000 1,244,400 651,240
Olyset Plus (contains PBO) 1,000,000 1,601,560 994,000
Total 8,967,360 10,159,920 8,967,360
LLIN long-lasting insecticidal net, PBO piperonyl butoxideaccordance with WHO recommendations, an allocation
formula was applied (total number of people in the house-
hold, divided by 2, and rounded up in the case of an un-
even number of household members) to determine the
number of nets each household was to receive [32]. Com-
munity members were mobilised and informed in advance
of the distribution.
Revised randomisation and net allocation
Distribution of LLINs in the first 44 clusters was com-
pleted by the Ministry of Health as scheduled, with nets
distributed in 24 PBO and 20 non-PBO clusters (Table
1). However, the number of nets distributed initially was
greater than estimated, resulting in a deficit of nets avail-
able for the final round of distribution within the study
area. After determining the total number of nets avail-
able, the 60 remaining clusters were re-randomised,
using the same process of adaptive randomisation de-
scribed above, such that the number of clusters assigned
to the two study arms (PBO versus non-PBO) balanced,
with 52 clusters assigned to each of the two study arms
in a 1:1 ratio (Table 1).
Data collection
Follow-up cross-sectional surveys
To evaluate the impact of the LLINs, cross-sectional sur-
veys of community residents will be conducted at 6, 12,
and 18 months post-distribution, following the same
methods as described above for the baseline surveys. In
brief, the follow-up community surveys will consist of a
household survey questionnaire administered to heads
of households, and a clinical survey of children aged 2–
10 years. Households will be randomly selected from
each of the 104 clusters using two-staged cluster sam-
pling until 50 households are enrolled per cluster (total
5200 households). The household questionnaire used for
the baseline surveys will be adapted for the follow-up
surveys to include specific questions about the LLINs
distributed by the Ministry of Health through the
national campaign. Random selection of households for
screening and enrolment will be repeated withl number of clusters allocated
number of
d
Number of clusters (health sub-districts) allocated
n
Final
randomisation
Waves 2
and 3
Wave 4 Western
region
Eastern
region
Total
3,830,280 16 21 24 13 37
3,515,520 18 14 16 16 32
1,239,640 4 11 11 4 15
1,574,480 6 14 15 5 20
10,159,920 44 60 66 38 104
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aged 2–10 years from enrolled households who are
present will be eligible to participate in the clinical sur-
vey. The primary outcome of the community surveys
will be malaria parasite prevalence as measured by mi-
croscopy. Entomological surveillance for insecticide re-
sistance will also be conducted concurrently with each
community survey, aiming to collect mosquitoes from
10 randomly selected households per clusters as de-
scribed above.
Phenotypic monitoring
We intend to conduct resistance phenotyping on mos-
quito samples collected from a sub-set of households
located in 12 sentinel site clusters, which will be pur-
posely selected based on the likelihood of collecting
large numbers of mosquitoes, supported by baseline
entomology data, and by proximity to the regional en-
tomology laboratories where the assays will be per-
formed. Six clusters will be selected from each region
(East and West), aiming to balance the net allocation
assignments in each region. In each cluster, approxi-
mately 10–15 households will be selected or approxi-
mately 120–180 households in total, per survey. The
same procedures described above will be followed for
recruitment, screening, consenting, surveying, and
mosquito collection, with one exception: households
may be visited more than once for mosquito collec-
tions. The live females collected will be tested for
susceptibility to the active ingredients used on the dis-
tributed LLINs (Olyset, permethrin; PermaNet, delta-
methrin) and in combination (permethrin + PBO and
deltamethrin + PBO). Susceptibility assays will be con-
ducted in line with WHO guidelines, and we will com-
bine standard WHO tube tests with intensity assays
where indicated. If the number of adult females ob-
tained from resting collections is too small they will be
supplemented by 3- to 5-day old females raised from
larval collections. We propose to test the susceptibility
of the three major vectors (An. gambiae, An. arabiensis
and An. funestus), but it is possible that too few mos-
quitoes will be collected to make an accurate assess-
ment of population susceptibility.
LLIN durability and bio-efficacy
Durability and bio-efficacy of the LLINs will be assessed
1 year after the distribution of nets, concurrently with
the 12-month cross-sectional survey. We will quantify
net durability and bioavailability of insecticides using
standard WHO methodologies. To assess LLIN durabil-
ity (the number, location, size, and type of holes in each
net), a sub-set of nets distributed during the 2016–2017
universal LLIN campaign will be withdrawn (and re-
placed) from households during the 12-month cross-sectional survey. We propose to sample 400 nets (100
per study arm) from randomly selected households
using the list of households selected for the
cross-sectional community surveys. During the cross-
sectional survey, availability of nets distributed during
the 2016–2017 universal LLIN campaign will be
assessed in selected households. If nets are available in
the household, one net per household will be with-
drawn (and replaced) for the durability assessment. We
will quantify durability of the net using the method-
ology developed by the WHO Vector Control Working
Group [33].
To assess LLIN bio-efficacy (the degree of knock-
down, mortality, or inhibition of blood-feeding induced
in susceptible mosquitoes, as determined by cone bioas-
says), the sub-set of 400 nets will also undergo bio-
efficacy assessments. We will use a standard laboratory
strain of An. gambiae from Kisumu, Western Kenya,
which is fully susceptible to both permethrin and delta-
methrin in WHO discriminant dose tests. In brief, five
unfed 3- to 5-day-old mosquitoes will be exposed for 3
min to a net sample taken from the top of each net. The
rationale being that this is the first point of contact for a
mosquito taking a blood meal and ensures that we sam-
ple the dual treated surface on both types of PBO net
[34, 35]. Knock-down will be recorded 60 min post-
exposure and mortality after 24 h. Two net samples will
be used per net and five cone tests will be conducted
per sample together with appropriate negative controls.
For a subset of 20 nets of each type we will use the same
protocol but with a Ugandan pyrethroid resistant strain
which exhibits P450-mediated resistance to test for the
durability of PBO treatment on the dual-treatment nets.
Laboratory procedures
Microscopy
Thick blood smears will be made by placing a drop of
blood in the middle of a barcoded slide. Slides will be
dried and kept in the field for no longer than 7 days to
avoid auto-fixation. While in the field, slides will be
stored in a cool environment and protected from ex-
cess heat and sunlight. Blood samples will be trans-
ported periodically to the Infectious Diseases Research
Collaboration (IDRC) Molecular Research Laboratory
(MOLAB) in Kampala for reading. At the MOLAB,
thick blood smears will be stained with 2% Giemsa for
30 min and then evaluated for the presence of parasit-
aemia (asexual forms only). A thick blood smear will be
considered negative when the examination at 100×
high-power fields does not reveal asexual parasites. For
quality control, all slides will be read by a second
microscopist. If there is a discrepancy between the first
and second reads (defined as any of the following: 1) a
positive versus negative for asexual parasites, 2)
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sus negative for gametocytes), a third microscopist will
review the slide.
Haemoglobin measurement
Haemoglobin analysis will be carried out in eligible chil-
dren 2–4 years of age on site using a drop of blood
collected from a finger-prick using a battery-operated
portable analyser (HemoCue, Anglom, Sweden). Any par-
ticipant who is found to have severe anaemia (haemoglo-
bin < 7.0 g/dL) requiring treatment will be referred to an
appropriate healthcare facility for further management.
Filter paper samples
Blood spots will be collected onto filter paper to store for
future serologic and/or molecular studies which will be
performed only for research purposes and will have no
impact on the clinical management of study participants.
Filter paper (Whatman no 1, Whatman 3MM; Whatman,
Maidstone, UK) will be pre-cut into individual squares,
stapled to a thick card which will serve as its cover, and
will be labelled with a barcode. Blood spots will be col-
lected onto the filter paper in volumes of approximately
25-μl aliquots per blood spot (four blood spots per sam-
ple). Filter paper samples will be allowed to dry at ambient
temperature and relative humidity, transported from the
field in a zip lock bag, and will be placed into a stock card
filter paper box for final storage with a desiccant.
Rapid diagnostic tests
RDTs (SD Bioline Malaria Ag P.f or P.f/Pan, Standard
Diagnostics, Inc.) will be performed in the field on
cross-sectional survey participants who are found to have
a temperature ≥ 38.0 °C or who report fever in the past 48
h. RDTs will be performed according to the directions
provided for the specific tests, using the blood transfer de-
vice and reagent provided by the manufacturer. Tests will
be performed by study personnel, and results will be avail-
able within 15min. The results of the RDT will be pro-
vided to the participant’s caregiver verbally and will be
recorded on the appropriate case record form. Partici-
pants who test positive for malaria will be provided with a
full course of anti-malarial treatment and will also be
counselled to go to the nearest healthcare facility immedi-
ately if their condition worsens.
Insecticide resistance monitoring
We plan to use a combination of single nucleotide
polymorphisms in the P450 Cyp4j5 and the esterase
Coeae1d which were reproducibly associated with pyr-
ethroid resistance in multiple field collections from
Uganda and Kenya, and which together with the
Vgsc-1014S (kdr) mutation explained around 20% of
variation in pyrethroid resistance [17]. These will besupplemented by Ugandan-specific resistance markers
identified through the Anopheles gambiae 1000 ge-
nomes project (Ag1000G), and allied projects [30, 36].
Female anopheles mosquitoes collected from the 104
clusters during the entomology surveys will be identi-
fied and will be stored and refrigerated in the field sites
prior to shipment to Kampala and onto LSTM for fur-
ther analysis.
Data management
All data will be collected by survey teams using hand-held
tablet computers. Prior to conducting the surveys, infor-
mation from the questionnaires and fields for entering re-
sults of laboratory testing will be programmed into the
tablet computers. Programming will include range checks,
structure checks, and internal consistency checks. Before
leaving the household, an inventory will be made of the
completed questionnaires and blood samples collected;
both will be checked to make sure they are labelled cor-
rectly. The completed questionnaires will be checked for
mistakes and completeness. Data from these devices will
be transferred at the end of every day to our data core fa-
cilities in Kampala and stored on a secure server. The data
file will be kept on a separate network so that only autho-
rized survey staff will have access to the data during col-
lection and the processing phase. The file with data from
the questionnaires will be merged with results from read-
ing the malaria slides at the laboratory, using the unique
bar codes. All filter paper samples and blood slides will be
returned to the IDRC offices in Kampala.
Laboratory data, including results of microscopy, will
be recorded by study personnel on standardized data
forms. Data entered onto paper record forms will be
entered into a computerised database (Microsoft Ac-
cess) by a data entry clerk and will be double-entered
to verify accuracy. An audit trail of the date and time of
data entry, and a record of any changes made, will be
kept in compliance with Good Clinical Practice (GCP).
All study personnel will be trained in the project objec-
tives, methods of effective communication with study
participants, collection of high-quality data, and princi-
ples of ethical research practice. Study personnel mem-
bers will receive additional training specific to the tasks
they will perform within the project including inter-
viewing techniques, administration of surveys, complet-
ing questionnaires, and use of tablet devices. Standard
operating procedures (SOPs) will be written for all pro-
ject activities, and booklets of all relevant documents
provided to each member of the project team.
Records for this study will be maintained and stored in
compliance with the principles of GCP and regulatory
and institutional requirements, and in compliance with
the requirements for the protection of confidentiality of
participants.
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Community surveys
The study sample size (number of clusters and allocation
of interventions) was set by the number of nets available
for the four different types of study nets and the esti-
mated number of LLINs required per cluster. We will
sample all eligible children aged 2–10 years from 50
households in the 104 clusters in each round of surveys,
resulting in an estimated total of 10,400 children from
5200 households per survey. Assuming a parasite preva-
lence of 40% in the control arm [25], and coefficient of
variation between clusters of 0.3 (derived from the on-
going trial in Tanzania [21]), we will have 80% power
(two-sided significance level of 0.05) to detect a relative
reduction in parasite prevalence of at least 17% (preva-
lence ratio of 0.83).Entomology surveys
We aim to collect 30–50 mosquitoes per cluster. The
sample sizes were chosen based on the expected fre-
quency (50 to 60%) of the known resistance-associated
P450 variant (Cyp4j5) in Eastern Uganda [17]. Therefore,
a relatively small sample size is required for an accurate
estimate of resistance marker frequency. However, we are
aware that resistance is a highly dynamic system and that
we may need to increase the number of mosquitoesTable 2 Outcome measure definitions
Indicator de
Community survey
Prevalence of parasitaemia Proportion o
Prevalence of anaemia Proportion o
LLIN coverage Proportion o
Proportion o
Average num
Average num
Proportion o
Proportion o
Proportion o
Insecticide resistance
Phenotyping Prevalence o
Genotyping Prevalence o
LLINs
Survivorship Proportion o
Proportion o
Durability Proportionat
1) good, 2) s
Bio-efficacy Knock-down
Mortality rat
LLIN long-lasting insecticidal netanalysed in certain clusters if resistance marker frequen-
cies change dramatically.
Analytical issues
Primary and secondary outcomes
The primary and secondary outcomes are outlined in
Table 2.
Statistical methods
All data will be analysed on the basis of intention-
to-treat and per-protocol analyses. Intention-to-treat
analyses will include the assigned treatment arms and
results from all clusters. For per-protocol analyses, clus-
ters will be grouped by treatment arm according to the
type of LLINs actually received in the national campaign.
For clusters with mixed LLIN distribution, the number
of nets from the dominant type received (numerator)
will be divided by the total number of the four study net
types received in that cluster, excluding non-study nets
(denominator). To be included in the per-protocol
analyses, the proportion of the dominant net received in
the cluster must be > 75% out of the four study net
types. Clusters in which the dominant net type received
is ≤ 75% will be excluded from the per-protocol analyses.
The primary outcome will be the prevalence of asexual
parasitaemia from the cross-sectional surveys. An
individual-level approach to the analysis will be used duefinition
f thick blood smears that are positive for asexual parasites
f haemoglobin measurements categorized as anaemia (< 10.0 g/dL)
f households owning at least one net
f households owning at least one LLIN
ber of nets per household
ber of LLINs per household
f households with one LLIN for every two residents
f children who slept under an LLIN the prior night
f pregnant women who slept under an LLIN the prior night
f phenotypic insecticide resistance
f molecular markers associated with insecticide resistance
f households owning at least one 2016–2017 campaign net
f households using at least one 2016–2017 campaign net the prior night
e Hole Index (PHI):
erviceable (repairable), or 3) in need of replacement
rate at 60 min of mosquitoes tested
e of mosquitoes tested
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of the primary outcome between treatment arms, gener-
alized linear Poisson models with a log-link function will
be used to allow for within-cluster correlations adjusting
for baseline cluster-level parasite prevalence. The effect
of the intervention will be quantified by calculation of a
prevalence ratio. Separate analyses will be performed
using data from the post-distribution cross-sectional sur-
veys (performed 6, 12, and 18 months after the delivery
of the nets).Sub-group analyses
Stratified sub-group analyses will be performed at the level
of the region (Western or Eastern) and net manufacturer
(PermaNet or Olyset). Spatial auto-correlation in insecti-
cide resistance will also be explored to interpolate resist-
ance patterns collected at the household level.Monitoring
Given the nature of this trial, in which the intervention
(LLINs) is delivered as a national programme by the
Uganda Ministry of Health, no data and safety monitor-
ing committee was established, and we have no plans for
an interim analysis. Moreover, as the investigators are
responsible only for the evaluation, we have no plans for
monitoring adverse events. Internal audits of the trial
are being conducted for each round of surveys by the
IDRC’s regulatory department.Ethical issues
Research ethics approval
The trial has been approved by the Ugandan National
Council for Science and Technology (UNCST; ref. HS
2176), Makerere University School of Medicine Research
& Ethics Committee (SOMREC; 2016–133), London
School of Hygiene and Tropical Medicine Ethics Com-
mittee (LSHTM; ref. 12019), and the Liverpool School of
Tropical Medicine (LSTM; ref. 16–072), which spon-
sored the study.Protocol amendments
Approval of the original study protocol (V2.0, 1 February
2017) was obtained from all of our Institutional Review
Boards (IRBs) on 13 March 2017. The protocol was sub-
sequently amended (Version 3.0, 15 August 2017), and
was fully approved on 1 November 2017. For any future
protocol amendments, investigators will be notified, IRB
approval will be sought, and the clinical trial registry
will be updated. For the SPIRIT 2013 Checklist of
recommended items to include in an interventional trial
protocol, see Additional file 2.Informed consent
Approval from local leaders will be sought before be-
ginning activities in the project area. Written informed
consent to participate in the study will be obtained by
the head of household (or their designate) for all house-
holds participating in the community and entomology
surveys. Written consent to participate in the clinical
survey will be obtained from parents or guardians of all
children. In all cases involving participation of children
aged 8 years or older, written assent will also be ob-
tained from the child. All informed consent discussions
will be conducted in the appropriate local language,
and a translator will be used if necessary. Information
sheets and consent forms will be available in English
and appropriate local languages, describing the purpose
of the project and the procedures to be followed, and
the risks and benefits of participation. During the con-
sent discussions, each section of the consent form will
be read exactly as it is written either by study personnel
or by the translator, and then further explained to the
respondent (participant or parent/guardian) if neces-
sary. The translator will also assist with the discussion
and assessment of comprehension. All participants and
parents/guardians will be informed that participation in
the study is completely voluntary and that they may
withdraw from the study at any time. If the person
asked to provide consent is unable to read or write,
their fingerprint will substitute for a signature, and a
signature from a witness to the informed consent pro-
cedures will be obtained. Written consent for future
use of biological specimens will also be obtained for the
community surveys.Confidentiality
Records for this study will be maintained and stored in
compliance with the principles of GCP and regulatory
and institutional requirements, and in compliance with
the requirements for the protection of confidentiality of
participants. Only study personnel will have access to
these records. All forms with participant names will be
kept in a locked cabinet when not in use. Participants
will be identified by their study ID number, and partici-
pant names will not be included in databases used for
analysis. Data will be stored for at least 10 years. Anon-
ymized data collected in this study may also be shared
with other investigators and/or placed into the public
domain via a data repository.Ancillary and post-trial care
Given the nature of this trial, in which the intervention
(LLINs) is delivered as a national programme by the
Uganda Ministry of Health and the evaluation includes
assessments of community members at a single point
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post-trial care.
Dissemination policy
The final 18-month cross-sectional survey will be
conducted in September 2019. Laboratory testing,
data analyses, and preparation of the final manu-
script are expected to take until the end of 2019.
Peer-review and publication of the trial results are
anticipated in the first quarter of 2020. We plan to
disseminate the findings widely, sharing with the
sponsor and key stakeholders, including the Uganda
Ministry of Health and the National Malaria Con-
trol Division, the World Health Organization’s Vec-
tor Control Advisory Group, Innovative Vector
Control Consortium, President’s Malaria Initiative,
and Global Fund, among others. The results will
also be presented at national and international con-
ferences. Authorship for the Long-Lasting Insecti-
cidal Net Evaluation in Uganda Project (LLINEUP)
manuscripts was decided in advance by the core in-
vestigators; no professional writers will be used. Ac-
cess to the full protocol, participant-level dataset,
and statistical code will be available upon reasonable
request.
Trial status
The baseline community and entomology surveys
were carried out from March to June 2017. LLINs
were distributed in the study area between March
2017 and March 2018. The first round of follow-up
surveys (6 months) started in September 2017 and
the final round of surveys (18 months) are scheduled
to complete in September 2019. We are seeking fund-
ing for an additional round of surveys, which would
be conducted at 24–30 months following distribution
of the LLINs.
Discussion
The WHO has issued a preliminary endorsement of
PBO LLINs based on the results of a single trial con-
ducted in Tanzania, but additional evidence of the ef-
fect of PBO LLINs is urgently needed. Uganda, with its
persistently high burden of malaria and widespread pyr-
ethroid resistance, is an optimal setting to undertake
this evaluation. We have leveraged resources by apply-
ing a cluster-randomised design to a national LLIN dis-
tribution campaign aiming to achieve universal
coverage of LLINs in Uganda. Although this study
design, linking the evaluation to the national LLIN
campaign, presents substantial opportunities, it also
presents a few limitations. Because the nets were pro-
cured in advance of establishing the trial, the type and
number of nets were already fixed. Thus, we wererequired to use adaptive randomisation to accommo-
date for the differences in net availability. The shortage
of nets available for the final round of distribution in
the study area forced the Ministry of Health to source
additional nets; as a result, the research team had to
re-randomise the final 60 clusters. Moreover, the Minis-
try of Health and partners, not the research team, were
responsible for distributing the nets. Although we
worked closely with the Ministry of Health to ensure
that the LLINs were allocated according to the random-
isation list, there is a chance that the net distribution
was imperfect. Despite these challenges, this innovative
trial design demonstrates how policy makers,
programme implementers, and researchers can work
together to generate robust scientific evidence on the
impact of malaria control interventions delivered at a
national level.Roles and responsibilities
Investigators listed on the protocol
Principal investigator (PI): Prof. Janet Hemingway, CBE,
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Trial sponsor
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Tropical Medicine), MRK (Makerere University/Infec-
tious Diseases Research Collaboration), and GD (Univer-
sity of California, San Francisco). The funders played no
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Trial coordination
The project is coordinated by the core investigative
team, and field activities are carried out in Uganda by
the Infectious Diseases Research Collaboration led by
a local study coordinator. Daily management of the
trial is overseen by SGS supported by MRK; data
management is overseen by GD. No steering commit-
tee or endpoint adjudication committee have been
appointed for this trial.
Additional files
Additional file 1: World Health Organization trial registration dataset.
(PDF 118 kb)
Additional file 2: SPIRIT 2013 Checklist: standard protocol items:
recommendations for interventional trials. (DOC 123 kb)
Abbreviations
GCP: Good Clinical Practice; IDRC: Infectious Diseases Research Collaboration;
IRS: Indoor residual spraying; LLIN: Long-lasting insecticidal net; LLINEUP: Long-
Lasting Insecticidal Net Evaluation in Uganda Project; LSHTM: London School of
Hygiene and Tropical Medicine; LSTM: Liverpool School of Tropical Medicine;
PBO: Piperonyl butoxide; RDT: Rapid diagnostic test; SOP: Standard operating
procedure; UBOS: Uganda Bureau of Statistics; WHO: World Health Organization
Acknowledgements
We thank Susan Nayiga, Christine Nabirye, Lillian Taaka, Mary Kyohere, Agaba
Katureebe, Isiko Joseph, Erias Muyanda, Henry Opolot, Peter Mutungi, Simon
Peter Kigozi, Geoff Lavoy, Mugote Martin, Violet Tuhaise, Nicholas Wendo,
Maxwell Kilama, and the administration of the Infectious Diseases Research
Collaboration for all their contributions. We would also like to acknowledge
and thank the members of the Uganda National Malaria Control Division and
the Liverpool School of Tropical Medicine for logistical and other supportrendered. We are grateful to the district health, administrative, and political
leadership teams for all their support and guidance as we launched the trial
in the 48 districts of the study area.
Funding
This project was funded primarily by The Against Malaria Foundation, with
additional funding from the Department for International Development and
the Innovative Vector Control Consortium. The content of the manuscript is
solely the responsibility of the authors.
Availability of data and materials
Data sharing is not applicable for this article as no datasets were generated or
analysed during the current study. The final trial dataset will be prepared for
analysis by GD (University of California San Francisco) and will be shared initially
with SGS (LSHTM) and subsequently with all investigators. No contractual
agreements exist that would limit the investigators’ access to data.
Authors’ contributions
SGS, MRK, GD, and MJD conceived the study with input from JO, AY, and JH.
SGS, GD, and MJD developed the procedures and drafted the protocol with
MRK and JH. CM-S, SG, and AL developed the standard operating proce-
dures. All authors reviewed the protocol and gave permission for publication.
All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Ugandan National Council for Science and
Technology (UNCST; ref. HS 2176), Makerere University School of Medicine
Research & Ethics Committee (SOMREC; 2016–133), London School of Hygiene
& Tropical Medicine Ethics Committee (LSHTM; ref. 12019), and the Liverpool
School of Tropical Medicine (ref. 16-072), which sponsored the study. Written in-
formed consent to participate in the study will be obtained by the head of
household (or their designate) for all participating households.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1London School of Hygiene & Tropical Medicine, Keppel Street, London
WC1E 7HT, UK. 2Makerere University College of Health Sciences, Infectious
Diseases Research Collaboration, 2C Nakasero Hill Road, Kampala, Uganda.
3Department of Medicine, University of California, San Francisco, San
Francisco, CA 94110, USA. 4National Malaria Control Division, Uganda Ministry
of Health, Infectious Diseases Research Collaboration, 2C Nakasero Hill Road,
Kampala, Uganda. 5Infectious Diseases Research Collaboration, 2C Nakasero
Hill Road, Kampala, Uganda. 6Makerere University School of Public Health,
Infectious Diseases Research Collaboration, 2C Nakasero Hill Road, Kampala,
Uganda. 7Liverpool School of Tropical Medicine, Pembroke Place, Liverpool
L3 5QA, UK. 8National Malaria Control Division, Uganda Ministry of Health,
Kampala, Uganda.
Received: 2 November 2018 Accepted: 24 April 2019
References
1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle KE,
Moyes CL, Henry A, Eckhoff PA, et al. The effect of malaria control on
Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015.
https://doi.org/10.1038/nature15535.
2. World Health Organisation. World malaria report 2017. Geneva: World
Health Organisation; 2017. ISBN 978-92-4-156552-3
3. Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, Nsobya S, Staedke
SG, Donnelly MJ, Wabwire-Mangen F, Talisuna A, et al. Malaria in Uganda:
challenges to control on the long road to elimination: I. Epidemiology and
Staedke et al. Trials          (2019) 20:321 Page 13 of 13current control efforts. Acta Trop. 2012;121:184–95. https://doi.org/10.1016/j.
actatropica.2011.03.004.
4. Kamya MR, Arinaitwe E, Wanzira H, Katureebe A, Barusya C, Kigozi SP, Kilama
M, Tatem AJ, Rosenthal PJ, Drakeley C, et al. Malaria transmission, infection,
and disease at three sites with varied transmission intensity in Uganda:
implications for malaria control. Am J Trop Med Hyg. 2015;92:903–12.
https://doi.org/10.4269/ajtmh.14-0312.
5. Katureebe A, Zinszer K, Arinaitwe E, Rek J, Kakande E, Charland K, Kigozi R,
Kilama M, Nankabirwa J, Yeka A, et al. Measures of malaria burden after
long-lasting insecticidal net distribution and indoor residual spraying at
three sites in Uganda: a prospective observational study. PLoS Med. 2016;13:
e1002167. https://doi.org/10.1371/journal.pmed.1002167.
6. Raouf S, Mpimbaza A, Kigozi R, Sserwanga A, Rubahika D, Katamba H,
Lindsay SW, Kapella BK, Belay KA, Kamya MR, et al. Resurgence of malaria
following discontinuation of indoor residual spraying of insecticide in a
previously high transmission intensity area of Uganda. Clin Infect Dis. 2017.
https://doi.org/10.1093/cid/cix251.
7. Oxborough RM. Trends in US President’s Malaria Initiative-funded indoor
residual spray coverage and insecticide choice in sub-Saharan Africa (2008–
2015): urgent need for affordable, long-lasting insecticides. Malar J. 2016;15:
146. https://doi.org/10.1186/s12936-016-1201-1.
8. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria.
Cochrane Database Syst Rev. 2004:CD000363. https://doi.org/10.1002/
14651858.CD000363.pub2.
9. Kleinschmidt I, Bradley J, Knox TB, Mnzava AP, Kafy HT, Mbogo C, Ismail BA,
Bigoga JD, Adechoubou A, Raghavendra K, et al. Implications of insecticide
resistance for malaria vector control with long-lasting insecticidal nets: a
WHO-coordinated, prospective, international, observational cohort study.
Lancet Infect Dis. 2018. https://doi.org/10.1016/S1473-3099(18)30172-5.
10. World Health Organisation. Achieving and maintaining universal coverage
with long-lasting insecticidal nets for malaria control. Geneva: World Health
Organisation, Global Malaria Programme; 2017. WHO/HTM/GMP/2017.20
11. Wanzira H, Katamba H, Rubahika D. Use of long-lasting insecticide-treated
bed nets in a population with universal coverage following a mass
distribution campaign in Uganda. Malar J. 2016;15:311. https://doi.org/10.
1186/s12936-016-1360-0.
12. Hemingway J, Ranson H, Magill A, Kolaczinski J, Fornadel C, Gimnig J,
Coetzee M, Simard F, Roch DK, Hinzoumbe CK, et al. Averting a malaria
disaster: will insecticide resistance derail malaria control? Lancet. 2016;387:
1785–8. https://doi.org/10.1016/S0140-6736(15)00417-1.
13. Ranson H, Lissenden N. Insecticide resistance in African anopheles mosquitoes:
a worsening situation that needs urgent action to maintain malaria control.
Trends Parasitol. 2016;32:187–96. https://doi.org/10.1016/j.pt.2015.11.010.
14. Ochomo E, Chahilu M, Cook J, Kinyari T, Bayoh NM, West P, Kamau L,
Osangale A, Ombok M, Njagi K, et al. Insecticide-treated nets and protection
against insecticide-resistant malaria vectors in Western Kenya. Emerg Infect
Dis. 2017;23:758–64. https://doi.org/10.3201/eid2305.161315.
15. Bradley J, Ogouyemi-Hounto A, Cornelie S, Fassinou J, de Tove YSS,
Adeothy AA, Tokponnon FT, Makoutode P, Adechoubou A, Legba T, et al.
Insecticide-treated nets provide protection against malaria to children in an
area of insecticide resistance in Southern Benin. Malar J. 2017;16:225.
https://doi.org/10.1186/s12936-017-1873-1.
16. Muller P, Warr E, Stevenson BJ, Pignatelli PM, Morgan JC, Steven A,
Yawson AE, Mitchell SN, Ranson H, Hemingway J, et al. Field-caught
permethrin-resistant Anopheles gambiae overexpress CYP6P3, a P450
that metabolises pyrethroids. PLoS Genet. 2008;4:e1000286. https://doi.
org/10.1371/journal.pgen.1000286.
17. Weetman D, Wilding CS, Neafsey DE, Muller P, Ochomo E, Isaacs AT, Steen
K, Rippon EJ, Morgan JC, Mawejje HD, et al. Candidate-gene based GWAS
identifies reproducible DNA markers for metabolic pyrethroid resistance
from standing genetic variation in East African Anopheles gambiae. Sci Rep.
2018;8:2920. https://doi.org/10.1038/s41598-018-21265-5.
18. Pennetier C, Bouraima A, Chandre F, Piameu M, Etang J, Rossignol M, Sidick
I, Zogo B, Lacroix MN, Yadav R, et al. Efficacy of Olyset(R) Plus, a new long-
lasting insecticidal net incorporating permethrin and piperonyl-butoxide
against multi-resistant malaria vectors [corrected]. PLoS One. 2013;8:e75134.
https://doi.org/10.1371/journal.pone.0075134.
19. World Health Organisation. Report of the 15th WHOPES working group
meeting – review of Olyset® Plus, Interceptor® LN, Malathion 440 EW,
Vectobac® GR, 18—22 June 201: World Health Organisation; 2012. ISBN 978
92 4 150408 9 and WHO/HTM/NTD/WHOPES/2012.520. World Health Organisation. Report of the 12th WHOPES Working Group
meeting – review of Bioflash® GR, Permanet® 2.0, Permanet® 3.0, Permanet®
2.5, Lambda-cyhalothrin LN, 8—11 December 2008. Geneva: World Health
Organisation; 2008. WHO/HTM/NTD/WHOPES/2009
21. Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD,
Manjurano A, Mosha FW, Kisinza W, Kleinschmidt I, Rowland M. Effectiveness
of a long-lasting piperonyl butoxide-treated insecticidal net and indoor
residual spray interventions, separately and together, against malaria
transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised
controlled, two-by-two factorial design trial. Lancet. 2018;391:1577–88.
https://doi.org/10.1016/S0140-6736(18)30427-6.
22. World Health Organisation. Conditions for deployment of mosquito nets
treated with a pyrethroid and piperonyl butoxide. Programme GM. Geneva;
2017. WHO/HTM/GMP/2017.17
23. Uganda Bureau of Statistics (UBOS) and the National Malaria Control
Programme of the Ugandan Ministry of Health. Uganda Malaria Indicator
Survey 2014–15. Kampala: Uganda Bureau of Statistics, National Malaria
Control Programme, Uganda Ministry of Health, Uganda Malaria Surveillance
Project Molecular Laboratory, ICF International; 2015.
24. Steinhardt LC, Yeka A, Nasr S, Wiegand RE, Rubahika D, Sserwanga A, Wanzira
H, Lavoy G, Kamya M, Dorsey G, Filler S. The effect of indoor residual spraying
on malaria and anemia in a high-transmission area of northern Uganda. Am J
Trop Med Hyg. 2013;88:855–61. https://doi.org/10.4269/ajtmh.12-0747.
25. Uganda Bureau of Statistics (UBOS) and ICR Macro. Uganda Malaria
Indicator Survey 2009. Calverton: UBOS and ICF Macro; 2010.
26. Yeka A, Nankabirwa J, Mpimbaza A, Kigozi R, Arinaitwe E, Drakeley C,
Greenhouse B, Kamya MR, Dorsey G, Staedke SG. Factors associated with
malaria parasitemia, anemia and serological responses in a spectrum of
epidemiological settings in Uganda. PLoS One. 2015;10:e0118901. https://
doi.org/10.1371/journal.pone.0118901.
27. Staedke SG, Maiteki-Sebuguzi C, DiLiberto DD, Webb EL, Mugenyi L,
Mbabazi E, Gonahasa S, Kigozi SP, Willey BA, Dorsey G, et al. The impact of
an intervention to improve malaria care in public health centers on health
indicators of children in Tororo, Uganda (PRIME): a cluster-randomized trial.
Am J Trop Med Hyg. 2016. https://doi.org/10.4269/ajtmh.16-0103.
28. Vazquez-Prokopec GM, Galvin WA, Kelly R, Kitron U. A new, cost-effective,
battery-powered aspirator for adult mosquito collections. J Med Entomol.
2009;46:1256–9.
29. Ramphul U, Boase T, Bass C, Okedi LM, Donnelly MJ, Muller P. Insecticide
resistance and its association with target-site mutations in natural
populations of Anopheles gambiae from eastern Uganda. Trans R Soc Trop
Med Hyg. 2009;103:1121–6. https://doi.org/10.1016/j.trstmh.2009.02.014.
30. Wilding CS, Weetman D, Rippon EJ, Steen K, Mawejje HD, Barsukov I,
Donnelly MJ. Parallel evolution or purifying selection, not introgression,
explains similarity in the pyrethroid detoxification linked GSTE4 of
Anopheles gambiae and An. arabiensis. Mol Gen Genomics. 2015;290:201–
15. https://doi.org/10.1007/s00438-014-0910-9.
31. Mawejje HD, Wilding CS, Rippon EJ, Hughes A, Weetman D, Donnelly MJ.
Insecticide resistance monitoring of field-collected Anopheles gambiae s.l.
populations from Jinja, eastern Uganda, identifies high levels of pyrethroid
resistance. Med Vet Entomol. 2013;27:276–83. https://doi.org/10.1111/j.1365-
2915.2012.01055.x.
32. Uganda Ministry of Health. Mass distribution of long-lasting insecticide
treated nets to achieve universal coverage in Uganda: detailed
implementation guidelines for universal campaign 2016–2017. Kampala:
Ministry of Health; 2016.
33. Hakizimana E, Cyubahiro B, Rukundo A, Kabayiza A, Mutabazi A, Beach R,
Patel R, Tongren JE, Karema C. Monitoring long-lasting insecticidal net
(LLIN) durability to validate net serviceable life assumptions, in Rwanda.
Malar J. 2014;13:344. https://doi.org/10.1186/1475-2875-13-344.
34. Parker JE, Angarita-Jaimes N, Abe M, Towers CE, Towers D, McCall PJ.
Infrared video tracking of Anopheles gambiae at insecticide-treated bed
nets reveals rapid decisive impact after brief localised net contact. Sci Rep.
2015;5:13392. https://doi.org/10.1038/srep13392.
35. Lynd A, McCall PJ. Clustering of host-seeking activity of Anopheles gambiae
mosquitoes at the top surface of a human-baited bed net. Malar J. 2013;12:
267. https://doi.org/10.1186/1475-2875-12-267.
36. The Anopheles gambiae Genomes C, Miles A, Harding NJ, Bottà G, Clarkson
CS, Antão T, Kozak K, Schrider DR, Kern AD, Redmond S, et al. Genetic
diversity of the African malaria vector Anopheles gambiae. Nature. 2017;552:
96. https://doi.org/10.1038/nature24995.
